# R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

> **NCT05777369** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Mitoxantrone hydrochloride liposome
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine/Vindesine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05777369
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2023-08
- **Final completion:** 2024-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05777369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05777369, "R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05777369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*